The Korean Journal of Physiology and Pharmacology

The Korean Society of Pharmacology (대한약리학회)
권호 표지

Assessment of an Apo-1/Fas Promoter Polymorphism in Korean Schizophrenia Patients

  • Kim, Soon-Ae (Kohwang Medical Research Institute, College of Medicine, Kyung Hee University) ;
  • Kim, Youn-Jung (Kohwang Medical Research Institute, College of Medicine, Kyung Hee University) ;
  • Choe, Bong-Keun (Kohwang Medical Research Institute, College of Medicine, Kyung Hee University) ;
  • Lee, Hee-Jae (Kohwang Medical Research Institute, College of Medicine, Kyung Hee University) ;
  • Kim, Jong-Woo (Seoul National University Mental Hospital) ;
  • Park, Jong-Deuk (Kimcheon Medical Hospital) ;
  • Kim, Chang-Ju (Kohwang Medical Research Institute, College of Medicine, Kyung Hee University) ;
  • Park, Seung-Joon (Kohwang Medical Research Institute, College of Medicine, Kyung Hee University) ;
  • Jung, Jee-Chang (Kohwang Medical Research Institute, College of Medicine, Kyung Hee University) ;
  • Chung, Joo-Ho (Kohwang Medical Research Institute, College of Medicine, Kyung Hee University)
  • Published : 2002.06.21
Download PDF
⟨ Previous Next ⟩

Abstract

Apoptosis has been hypothesized to be involved in the pathogenesis in schizophrenia. A large number of genes are known to mediate the apoptotic process; Apo-1/Fas (CD95) is a well-known example of such genes. In the present study, MvaI restriction fragment length polymorphism, a polymorphic marker present within the Apo-1/Fas gene, was examined in a population consisting of 226 control subjects and 110 schizophrenia patients, all of them Korean in ethnicity. No statistically significant difference in the genotypic distribution and allelic frequencies was observed between the control and the schizophrenia patient group. To find out the precise effect of Apo-1/Fas gene polymorphisms on the susceptibility to schizophrenia, further studies are warranted to investigate possible involvement of other polymorphisms with a larger sample population.

Keywords

References

  1. Catts VS, Catts SV. Apoptosis and schizophrenia: is the tumour suppressor gene, p53, a candidate susceptibility gene? Schizophr Res 41(3): 405-415, 2000
  2. Cheng J, Liu C, Koopman WJ, Mountz JD. Characterization of human Fas gene. Exonlintron organization and promoter region. J Immunol 154(3): 1239-1245, 1995
  3. DelaMonte SM, Sohn YK, Ganju N, Wands JR. p53- and CD95associated apoptosis in neurodegenerative diseases. Lab Invest 78(4): 401-411, 1995
  4. DelaMonte SM, Sohn YK, Wands JR. Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease. J Neurol Sci 152(1): 73 - 83, 1995
  5. Harrison PJ. Schizophrenia: a disorder of neurodevelopment? Curr Opin. Neurobiol 7(2): 285-289, 1997
  6. Huang QR, Danis V, Lassere M, Edmonds J, Manolios N. Evalulation of a new Apo-l/Fas promoter polymorphism in rhuemtoid arthritis and systemic lupus erythematosus patients. Rhematology (Oxford) 38(7): 645-651, 1999
  7. Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-l/Fas (CD95) gene. Mol Immunol 34(8-9): 577-582, 1997
  8. Huang QR, Teutsch SM, Buhler MM, Bennetts BH, Heard RN, Manolios N, Stewart GJ. Evaluation of the apo-l/Fas promoter Mva I polymorphism in multiple sclerosis. Mult SeZer 6(1): 1418, 2000
  9. Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C, Schmidt A, Debatin KM, Krammer PH, Moller P. Constitutive and induced expression of Apo-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 69(4): 415 - 429, 1993
  10. Mortensen PB. The incidence of cancer in schizophrenic patients. J Epulemiol Community Health 43(1): 43-47, 1989
  11. Mortensen PE. The occurrence of cancer in first admitted schizophrenic patients. Schizophr Res 12(3): 185-194, 1994
  12. Nagata S. Apoptosis regulated by a death factor and its receptor: Fas ligand and Fas. Philos Trans R Soc Land B Bioi Sci 345 (1313): 281- 287, 1994
  13. Rudert F, Visser E, Forbes L, Lindrige E, Wang Y, Watson J. Identification of a silencer, enhancer, and basal promoter region in the human CD95 (Fas/Apo-1) gene. DNA Cell Bioi 14(11): 931-937, 1995
  14. Seidl R, Fang-Kircher S, Bidmon B, Cairns N, Nubec G. Apoptosisassociatedproteins p53 and Apo-l/Fas (CD95) in brains of adult patients with Down syndrome. Neurosci Lett 260(1): 9 -12, 1999
  15. Shuai K. Interferon-activated signal transduction to the nucleus. Curr Opin Cell Bioi 6(2): 253 -259, 1994